2868892
Last Update Posted: 2018-11-02
Recruiting has ended
All Genders accepted | 18 Years + |
6 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas
Patients with advanced or recurrent adenocarcinoma or adenosquamous cell carcinoma of the cervix will receive Pemetrexed.
Patients will receive Pemetrexed 500 mg/m2 every three week.
On initiation of pemetrexed, on day one of first chemotherapy cycle, patients will begin taking folic acid at a dose of 350 to 600 mcg daily as well as receive an intramuscular injection of 1000 mcg of vitamin B12, with subsequent vitamin B12 injections given every 9 weeks while on study.
Eligibility
Relevant conditions:
Adenocarcinoma of the Cervix
Adenosquamous Cell Carcinoma of the Cervix
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov